Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Q2 FY24: Revenue ₹6,435 Cr, PAT ₹317 Cr
Q2 FY24 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹156Cr
- Net profit
- ₹28Cr
- Margin
- 20%
Guidance rank: #54 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Lincoln Pharmaceuticals Ltd Q2 FY24 key numbers
- Revenue
- Revenue: ₹6,435 crore, up 19% year-on-year.
As stated in Lincoln Pharmaceuticals Ltd's Q2 FY24 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Lincoln Pharmaceuticals Ltd's Q2 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
The investor presentation (Quarter 2, 2023-24) reports the following: - Revenue: ₹6,435 crore, up 19% year-on-year. - Volume: 3.19 billion liters, up 12% year-on-year. - Sales growth: Domestic sales volume increased by 12%; International sales increased by 15%. - Outlook: The presentation states a positive outlook with expectations of sustained volume growth driven by premiumization and market expansion. EBITDA for the quarter: ₹482 crore, up 26% YoY - Operating margin for the quarter: 22.7%, expanded by 120 basis points YoY - Profit after tax (PAT) for the quarter: ₹317 crore, up 30% YoY - The
From Lincoln Pharmaceuticals Ltd's Q2 FY24 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
2 more points from Lincoln Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Lincoln Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
2 more points from Lincoln Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Lincoln Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Lincoln Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.
Lincoln Pharmaceuticals Ltd — Quarterly revenue & net profit
Lincoln Pharmaceuticals Ltd Q2 FY24 results — key figures
| ₹ Cr | Q2 FY24 |
|---|---|
| Revenue | 156 |
| Operating profit (EBITDA) | 31 |
| Operating margin | 20% |
| Profit before tax | 37 |
| Net profit (PAT) | 28 |
| EPS (₹) | 13.80 |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹191 Cr, net profit ₹20 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Lincoln Pharmaceuticals's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q2 FY25 earnings call analysis →
- Q4 FY24 earnings call →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- P & G Health Ltd (Q2 FY24)
Reported revenue: ₹1230 crore (page 17) . Key concall takeaways from Procter & Gamble Health Ltd's Q2 FY24 earnings call — and how it ranks against sector…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Lincoln Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Lincoln Pharmaceuticals Ltd Q2 FY24 results?
The investor presentation (Quarter 2, 2023-24) reports the following: - Revenue: ₹6,435 crore, up 19% year-on-year. - Volume: 3.19 billion liters, up 12% year-on-year. - Sales growth: Domestic sales volume increased by 12%; International sales increased by 15%. - Outlook: The presentation states a positive outlook with expectations of sustained volume growth driven by premiumization and market expansion. EBITDA for the quarter: ₹482 crore, up 26% YoY - Operating margin for the quarter: 22.7%, expanded by 120 basis points YoY - Profit after tax (PAT) for the quarter: ₹317 crore, up 30% YoY - The
What is Lincoln Pharmaceuticals Ltd share price analysis?
Lincoln Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 12.6 with a market cap of ₹1,212 Cr. Investors should review the full earnings analysis for detailed insights.
Is Lincoln Pharmaceuticals Ltd planning capital expenditure?
The presentation states the following on capex, capacity expansion, and new projects: - Capex: Planned capital expenditure of approximately INR 2,000 crore for FY2023-24.
Keep Lincoln Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.